We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.50 | 2.52% | 61.00 | 57.00 | 65.00 | 61.00 | 59.50 | 59.50 | 12,246 | 14:00:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investment Advice | 149k | -7.14M | -0.1082 | -5.64 | 39.26M |
RNS No 2903d CELSIS INTERNATIONAL PLC 12th May 1998 Board Changes Celsis International plc ('Celsis'), the microbial risk management group, announces that Arthur Holden has today resigned as Chief Executive Officer due to a conflict of interest. Mr Holden has informed the Board of his interest in exploring options such as acquiring or taking the company private. The Board believes that it is now appropriate for Celsis to have a Chief Executive who is resident in the UK. The Board would like to take this opportunity to thank Mr Holden for his contribution to the development of Celsis since 1994 and wish him the best for the future. Following his departure, two further board changes have been made: Jack Rowell has been appointed Acting Chief Executive, relinquishing his role as Chairman, and will manage the executive team and the Company's world-wide operations from its Cambridge headquarters pending the appointment of a new Chief Executive. Dr. Chris Evans, currently a Non-Executive Director, has been appointed Chairman and will focus on strategic initiatives, commercial activities and development of the new product pipeline. Celsis announces its preliminary results for the year ended 31 March 1998 today. Enquiries: Celsis International plc Dr Chris Evans, Chairman Jack Rowell, Acting Chief Executive 0171 404 5959, (For today only) Brunswick Group Susan Gilchrist / James Garthwaite 0171 404 5959 END BOANFXSAFDLPEEN
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions